Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0021 | 0.0743 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.016 | 0.9797 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0109 | 0.6497 | 0.6497 |
Brugia malayi | MH2 domain containing protein | 0.0115 | 0.6858 | 0.7 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0109 | 0.6497 | 0.6631 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0115 | 0.6858 | 0.7 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0021 | 0.0743 | 0.0759 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0.9797 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 0.0743 | 0.0743 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0051 | 0.2666 | 0.2666 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.0743 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0115 | 0.6858 | 0.7 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0021 | 0.0743 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0021 | 0.0743 | 0.5 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0021 | 0.0743 | 0.0743 |
Schistosoma mansoni | hypothetical protein | 0.0051 | 0.2666 | 0.2666 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0.0743 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.016 | 0.9797 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0109 | 0.6497 | 0.6631 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0051 | 0.2666 | 0.2666 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0021 | 0.0743 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0051 | 0.2666 | 0.2666 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.0743 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0051 | 0.2666 | 0.2666 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.0743 | 0.5 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0021 | 0.0743 | 0.0743 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0021 | 0.0743 | 0.5 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0051 | 0.2666 | 0.2666 |
Toxoplasma gondii | exonuclease III APE | 0.0021 | 0.0743 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.016 | 0.9797 | 1 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0051 | 0.2666 | 0.2666 |
Schistosoma mansoni | hypothetical protein | 0.0051 | 0.2666 | 0.2666 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0021 | 0.0743 | 0.0759 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0021 | 0.0743 | 0.5 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0051 | 0.2666 | 0.2722 |
Echinococcus multilocularis | GPCR, family 2 | 0.0051 | 0.2666 | 0.2666 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.2666 | 0.2722 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0.0743 | 0.5 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0051 | 0.2666 | 0.2722 |
Echinococcus granulosus | GPCR family 2 | 0.0051 | 0.2666 | 0.2666 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0051 | 0.2666 | 0.2722 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.0743 | 0.5 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0021 | 0.0743 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0021 | 0.0743 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 0.0743 | 0.0743 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.